Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Imrie

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantationC Girouard, J Dufresne, K Imrie, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2001
ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cellsE Gitelson, A Ghose, R Buckstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Ovarian function after autologous bone marrow transplantationA D Schimmer, M Quatermain, K Imrie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantationJ Mangel, R Buckstein, K Imrie, et al.
British Journal of Haematology|April 1, 1996
Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collectionsH M Prince, K Imrie, D R Sutherland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysisJ Mangel, H A Leitch, J M Connors, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupT Baetz, A Belch, S Couban, et al.
Seminars in Oncology|November 24, 1999
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphomaR Buckstein, K Imrie, D Spaner, et al.
Bone Marrow Transplantation|February 13, 2002
Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphomaN L Berinstein, R Buckstein, K Imrie, et al.
Bone Marrow Transplantation|November 26, 2008
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphomaL K Hicks, A Woods, R Buckstein, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1997
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantationC Girouard, J Dufresne, K Imrie, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2001
ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cellsE Gitelson, A Ghose, R Buckstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Ovarian function after autologous bone marrow transplantationA D Schimmer, M Quatermain, K Imrie, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantationJ Mangel, R Buckstein, K Imrie, et al.
British Journal of Haematology|April 1, 1996
Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collectionsH M Prince, K Imrie, D R Sutherland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysisJ Mangel, H A Leitch, J M Connors, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials GroupT Baetz, A Belch, S Couban, et al.
Seminars in Oncology|November 24, 1999
Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphomaR Buckstein, K Imrie, D Spaner, et al.
Bone Marrow Transplantation|February 13, 2002
Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphomaN L Berinstein, R Buckstein, K Imrie, et al.
Bone Marrow Transplantation|November 26, 2008
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphomaL K Hicks, A Woods, R Buckstein, et al.
Pageof 4